Samsung Biologics Co. Ltd.
Samsung Biologics Co. Ltd.
10/13/2025 | News release | Distributed by Public on 10/13/2025 18:26
Samsung Biologics to attend BIOPLUS-INTERPHEX KOREA 2025
UPDATE |October 14, 2025
Samsung Biologics to attend BIOPLUS-INTERPHEX KOREA 2025
- COPY
Samsung Biologics will participate in BIOPLUS-INTERPHEX KOREA 2025, which takes place in Seoul from October 15 to 17.
Samsung Biologics will showcase its end-to-end integrated CDMO services spanning drug screening, late discovery, and manufacturing, designed to help clients advance their pipelines efficiently from concept to market.
At Booth #K32, Samsung Biologics will also highlight ExellenSTM, its recently unveiled manufacturing framework optimized across the company's biomanufacturing network. ExellenSTM enables on-time project delivery and manufacturing excellence, which ultimately brings life-saving therapies to patients faster and with greater flexibility.
On the 16th, Taeheui Lee, Vice President of Ab Cell Purification Process Development, will deliver a session on streamlining drug development to accelerate timelines, showing Samsung Biologics' expertise in process optimization and operational excellence.
By participating, Samsung Biologics aims to contribute to meaningful discussions on the future of biomanufacturing and to share insights on how collaborative innovation can help bring novel therapies to patients faster.
Samsung Biologics will participate in BIOPLUS-INTERPHEX KOREA 2025, which takes place in Seoul from October 15 to 17.
Samsung Biologics will showcase its end-to-end integrated CDMO services spanning drug screening, late discovery, and manufacturing, designed to help clients advance their pipelines efficiently from concept to market.
At Booth #K32, Samsung Biologics will also highlight ExellenSTM, its recently unveiled manufacturing framework optimized across the company's biomanufacturing network. ExellenSTM enables on-time project delivery and manufacturing excellence, which ultimately brings life-saving therapies to patients faster and with greater flexibility.
On the 16th, Taeheui Lee, Vice President of Ab Cell Purification Process Development, will deliver a session on streamlining drug development to accelerate timelines, showing Samsung Biologics' expertise in process optimization and operational excellence.
By participating, Samsung Biologics aims to contribute to meaningful discussions on the future of biomanufacturing and to share insights on how collaborative innovation can help bring novel therapies to patients faster.
#Bioplus Interphex Korea
Share article
- COPY
Back to List
Related Content
Samsung Biologics Co. Ltd. published this content on October 13, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 14, 2025 at 00:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]